Scott Hutton Sells 83,660 Shares of Biodesix, Inc. (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton sold 83,660 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the transaction, the chief executive officer now owns 701,947 shares in the company, valued at $645,791.24. This trade represents a 10.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Biodesix Price Performance

NASDAQ BDSX opened at $0.96 on Friday. Biodesix, Inc. has a 12 month low of $0.86 and a 12 month high of $2.04. The stock has a market cap of $140.09 million, a price-to-earnings ratio of -2.47 and a beta of 1.06. The company’s 50 day moving average is $1.24 and its two-hundred day moving average is $1.49. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30.

Institutional Investors Weigh In On Biodesix

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. AIGH Capital Management LLC raised its stake in Biodesix by 8.8% during the 4th quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock worth $9,455,000 after acquiring an additional 500,000 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Biodesix during the 3rd quarter worth approximately $10,849,000. Samjo Management LLC bought a new stake in Biodesix during the 4th quarter worth approximately $3,790,000. Perkins Capital Management Inc. grew its holdings in Biodesix by 46.3% during the 4th quarter. Perkins Capital Management Inc. now owns 1,060,211 shares of the company’s stock valued at $1,622,000 after buying an additional 335,429 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Biodesix by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock valued at $1,266,000 after buying an additional 22,623 shares in the last quarter. Institutional investors own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.